The DOI matches its Crossref record; 98 of the 103 references it cites were found in a registry or an index, and 1 are not checked yet; 61 of the 148 sources its claims cite were checked for support.
The risks versus the benefits of pharmacological intervention in social anxiety disorder in children
Open accessAbstract
Introduction Many children are affected by social anxiety disorder (SAD). Pharmacotherapy, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), may be indicated, but a clear understanding of the risks and benefits associated with these pharmacological treatments is needed. Areas covered This expert review explores the risks and benefits of pharmacotherapy for treating SAD in children. Expert opinion Pharmacotherapy may be considered as a treatment when symptoms are complex or severe or when effective psychotherapy, such as cognitive behavioral therapy (CBT), is not accessible. We recommend that clinicians collaborate closely with parents, pediatricians, and psychiatrists in the treatment planning process, while monitoring the effects of pharmacotherapy. Future research should prioritize the personalization of treatments.
Verified 2026-10-05 · 1 reference not checked yet
Overview
CoChat Summary
TL;DR
This expert review concludes that CBT should remain first-line for pediatric social anxiety disorder (SAD), with SSRIs/SNRIs considered mainly when symptoms are severe or psychotherapy is inaccessible or ineffective. Pharmacotherapy can reduce anxiety symptoms, but it carries risks including suicidality, behavioral changes, and physical side effects, and no SSRI or SNRI is FDA-approved for SAD in children.
Key findings
- The 6-month prevalence of SAD in children is estimated at 5%; comorbidities are common, with rates of 77% in ages 6–9, 74% in ages 10–14, and 69% in ages 15–18 in one cited study.
- Medication trials show benefit over placebo: sertraline response 54.9% vs 23.7% for placebo after 12 weeks; fluvoxamine “much improved” in 76% vs 29% for placebo; venlafaxine response 56% (95% CI 47–64) vs 37% (95% CI 29–45) for placebo, with three venlafaxine-treated participants developing treatment-emergent suicidality.
- CBT is supported as first-line treatment; CBT combined with sertraline is more effective than either alone, and CBT is associated with lower dropout than pharmacological treatments.
- Risks include increased suicidality, adverse behavioral changes (e.g., hyperactivity, irritability, impulsivity, hostility), physical side effects (e.g., gastrointestinal discomfort, sleep disturbance, reduced height growth/weight gain with fluoxetine), and an FDA black box warning for SSRIs; no SSRI or SNRI is officially FDA-approved for SAD.
Methods
- Expert review/scoping review of RCTs using PubMed and Scopus up to August 2024, with search terms “Pharmacotherapy treatment,” “social anxiety disorder,” and “children.”
- The search yielded 762 records; after duplicate removal, two authors independently and blindly reviewed 680 abstracts, leading to inclusion of 8 RCTs.
- Inclusion criteria: RCTs; experimental group received pharmacotherapy alone or combined with psychotherapy; child/adolescent sample; diagnosis of SAD or anxiety disorders including SAD. The review also included 2 reviews and 4 meta-analyses, plus one additional meta-analysis found through references.
Limitations
- The paper states that literature on long-term effects of SSRIs/SNRs in children is scarce, findings on prenatal SSRI exposure are conflicting, and biological benefits research is limited.
- It notes that one included meta-analysis had moderate heterogeneity and moderate risk of bias, and that one RCT had a small sample size (N = 30), limiting generalizability.
- Evident from the text: this is an expert/scoping review rather than a systematic meta-analysis, with no quantitative pooling or formal risk-of-bias assessment reported; the FDA warning cited was based primarily on adolescents with major depressive disorder, not SAD.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Valid · 15 Not valid · 63 Not checked · 35 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“These results must be interpreted with caution as one of the meta-analysis limitations is the moderate heterogeneity between studies and the moderate risk of bias that was found on a great proportion of the included studies.”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > 3.1. Meta-analysis and reviews
What the sources say
- Disputedcites [44] 44. Strawn JR, Mills JA, Sauley BA, et al. The impact of antidepressant dose and class on treatment response in pediatric anxiety disor- ders: a meta-analysis. J A Acad Child Adolesc Psychiatry. 2018;57 (4):235-244.e2. doi: 10.1016/j.jaac.2018.01.015 •• Meta-analyses that offers guidelines for the use of antidepres- sants in pediatric populations, highlighting their high efficacy and safety. Findings indicate that pediatric anxiety disorders often respond well to first-line pharmacological treatments, such as SSRIs and SNRIs. sourceExperimental — accuracy not yet measured
The Results section (Selection of Studies and Study Characteristics; page not provided) says risk of bias was low across studies, contrary to the claim that a great proportion had moderate risk of bias. The Discussion acknowledges differences between studies but does not characterize their heterogeneity as moderate. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“On the contrary, benzodiazepines and tricyclic antidepressants were not effective at promoting a decrease in anxiety symptoms.”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > 3.1. Meta-analysis and reviews
What the sources say
- Disputedcites [35] 35. Kodish I, Rockhill C, Varley C. Pharmacotherapy for anxiety disor- ders in children and adolescents. Dialog Clin Neuroscie. 2011;13 (4):439-452. doi: 10.31887/DCNS.2011.13.4/ikodish sourceExperimental — accuracy not yet measured
The Tricyclic antidepressants section says TCAs showed efficacy in several randomized trials of youth with anxiety, contrary to the claim that they were ineffective. The Other agents section says controlled trials do not support benzodiazepines in children, but also reports symptomatic benefit in open-label studies; the claim overlooks that qualification. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“With its sample, the participants treated with Tenoten reported a significant decrease in anxiety symptoms when compared to placebo.”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > Walkup et al. [37] RCT CBT and Sertraline
What the sources say
- Disputedcites [52] 52. da Costa CZ, de Morais RM, Zanetta DM, et al. Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents. J Child Adolesc Psychopharmacol. 2013;23(10):687-692. doi: 10.1089/cap.2012.0110 sourceExperimental — accuracy not yet measured
The Results (page unavailable) identify the study groups as clomipramine, fluoxetine, and placebo—not Tenoten. The Effects of treatment section (page unavailable) reports significantly lower scores on some anxiety measures for fluoxetine versus placebo, so the claim assigns that finding to the wrong treatment. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Untreated SAD can also lead to maladaptive coping mechanisms, such as substance abuse [26].”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > 1.3. Comorbidities
What the sources say
- Partly supportedcites [26] 26. Garcia-Lopez LJ, Bonilla N, Muela-Martinez JA. Considering comor- bidity in adolescents with social anxiety disorder. Psychiatry Investig. 2016;13(5):574-576. doi: 10.4306/pi.2016.13.5.574 sourceExperimental — accuracy not yet measured
The Introduction says SAD is a chronic condition associated with a substantially increased risk of substance abuse. It does not specify untreated SAD or describe substance abuse as a coping mechanism. (LLM, conf=0.83)
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Their short-term effectiveness in treating children diagnosed with anxiety disorders are well-established [30].”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > 1.4. Intervention strategies
What the sources say
- Supportedcites [30] 30. Snir A, Moskow DM, Hofmann SG. When is it appropriate to treat children with social anxiety, pharmacologically? Expert Opin Pharmacother. 2021;22(18):2423-2426. doi: 10.1080/14656566. 2021.1948015 source
Section 4 (“Is pharmacotherapy safe and effective?”) explicitly says that randomized, placebo-controlled trials have established a short-term benefit of SSRIs for childhood anxiety disorders, including social anxiety disorder. This directly supports the attributed claim. (LLM, conf=0.95)
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
72 more claims · 25 with their cited sources checked
Create a free account to see all 152 claims and to verify the 2 references still open.
- It may state two separate claims as one. 49
- Probably not a substantial claim. 33
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 4
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > Walkup et al. [37] RCT CBT and Sertraline
“As expected, a combination therapy of sertraline and CBT was more effective at anxiety remission than CBT and sertraline alone.”
§ The risks versus the benefits of pharmacological intervention in social anxiety disorder in children > Walkup et al. [37] RCT CBT and Sertraline
“Furthermore, combination therapy had less risk of remission, and a low number needed to treat with the youths that displayed higher anxiety levels at baseline.”
Citations
Cites
(1976) · Medical Entomology and Zoology · Cited by 8,899
A cognitive-behavioral model of anxiety in social phobia
Rapee, R. M., & Heimberg, R. G. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)00022-3 · Cited by 2,987
Social Anxiety among Adolescents: Linkages with Peer Relations and Friendships
La Greca, A. M., & Lopez, N. (1998) · Journal of Abnormal Child Psychology · doi:10.1023/a:1022684520514 · Cited by 1,656 · cited 1×
“Venlafaxine was more effective at reducing SAD than placebo, as measured with the SAS-CA [49].”
Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety
Walkup, J. T., Albano, A. M., Piacentini, J., Birmaher, B., Compton, S. N., Sherrill, J. T., Ginsburg, G. S., Rynn, M. A., McCracken, J., Waslick, B., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804633 · Cited by 1,442
Social Phobia: Diagnosis, Assessment, and Treatment
Amada, G. (1996) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1996.50.3.373 · Cited by 1,248
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Hofmann, S. G. (2007) · Cognitive Behaviour Therapy · doi:10.1080/16506070701421313 · Cited by 1,064 · cited 3×
“…maintain social anxiety and typically involve techniques such as cognitive restructuring, exposure therapy, and social skills training – which work together to help children challenge and modify their negative thought patterns, reduce avoidance behaviors, and improve their social functioning [18].”
InfluentialSelf-citationSSRI Antidepressant Medications: Adverse Effects and Tolerability
Ferguson, J. M. (2001) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v03n0105 · Cited by 669 · cited 1×
“Among these concerns is the association between this kind of intervention and the risk of depression and suicidality [73].”
Fluvoxamine for the Treatment of Anxiety Disorders in Children and Adolescents
Walkup, J. T., Labellarte, M. J., Riddle, M. A., Pine, D. S., Greenhill, L., Klein, R., Davies, M., Sweeney, M., Abikoff, H., Hack, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441703 · Cited by 588
Connolly, S. D., & Bernstein, G. A. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000246070.23695.06 · Cited by 548
Research works printed but not linked: 2
- 10.1056/nejm200104263441703 · DOI · Paper page
- 10.31887/DCNS.2011.13.4/ikodish · DOI · Paper page
Cited by
Virtual Reality as a Non-Pharmacological Aid for Reducing Anxiety in Pediatric Dental Procedures
Trusculescu, L.-M., Pitic, D. E., Sălcudean, A., Popovici, R. A., Forna, N. C., Bădoiu, S. C., Enache, A., Enasoni, S., Kiș, A. M., Cosoroabă, R. M., et al. (2025) · Children · doi:10.3390/children12070930 · Cited by 21
Efficacy of three virtual reality interventions for social anxiety disorder: A meta-analysis
He, X., Liu, Z., Ji, Y., Zou, C., & Liu, J. (2026) · Acta Psychologica · doi:10.1016/j.actpsy.2026.107811
Metadata
- Authors
- Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G.
- Affiliations
- Philipps University of Marburg (DE)
- Corresponding author
- Hofmann, Stefan G.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2025-02-12
- Volume
- 25
- Issue
- 3
- Pages
- 299-310
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W4407555893
- Cited by
- 2
- References
- 97
- Citations by year
- 2026: 1 · 2025: 1
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Neurotherapeutics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Keywords
- social anxiety disorder, children, pharmacotherapy, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment risks and benefits, cognitive behavioral therapy, treatment planning, parental collaboration, treatment monitoring, personalized treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The risks versus the benefits of pharmacological intervention in social anxiety disorder in children. https://app.cochat.ai/papers/10.1080/14737175.2025.2461763
- The paper
- Hofmann, S. G., Kasch, C., Pereira, B., Barbosa, C., & Andreoli, G. (2025). The risks versus the benefits of pharmacological intervention in social anxiety disorder in children. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2025.2461763
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.